In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SK Biopharmaceuticals Co. Ltd.

www.skbp.com/eng

Latest From SK Biopharmaceuticals Co. Ltd.

E2082 Discontinuation May Hit Eisai's Epilepsy Succession

Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.

Japan Clinical Trials

Korea Eases Stock Rules To Help Bioventures Stay Listed, Focus On R&D

South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities. 

South Korea Financing

Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Deals Business Strategies

KDDF’s Support Reflected In Robust R&D, Licensing By Korean Firms

Various government support schemes seem to have led to recent successful new drug development activities and licensing deals by South Korean pharma and biotech firms. The state-run Korea Drug Development Fund is seen as having played a key role in this effort, providing assistance to 153 R&D programs in the country so far to speed up development of novel and innovative global medicines.
Research & Development South Korea
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • SK Biopharmaceuticals Co. Ltd.
  • Senior Management
  • Jeong Woo Cho, PhD, Pres. & CEO
    Jiyoung Jung, VP, CFO
    Kiho Lee, PhD, VP, R&D
  • Contact Info
  • SK Biopharmaceuticals Co. Ltd.
    Pangyo,
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register